title: Immunomodulatory effects of fosfomycin in experimental human endotoxemia.
abstract: To evaluate the effect of fosfomycin on proinflammatory cytokines, a bolus of 2 ng of bacterial lipopolysaccharide/kg of body weight was injected intravenously into healthy volunteers. After 2 h, subjects received 8 g of fosfomycin or placebo in a randomized crossover study design. The resulting concentrations of tumor necrosis factor alpha, interleukin-1beta (IL-1beta), and IL-6 expressed as protein and mRNA levels were almost identical with and without fosfomycin.
authors.affiliation: Department of Clinical Pharmacology, Division of Pharmacokinetics, Medical University of Vienna, Vienna, Austria.
authors.forename: Robert
authors.initials: R
authors.lastname: Sauermann
authors.forename: Claudia
authors.initials: C
authors.lastname: Marsik
authors.forename: Ilka
authors.initials: I
authors.lastname: Steiner
authors.forename: Katja
authors.initials: K
authors.lastname: Seir
authors.forename: Tuende
authors.initials: T
authors.lastname: Cvitko
authors.forename: Markus
authors.initials: M
authors.lastname: Zeitlinger
authors.forename: Oswald
authors.initials: O
authors.lastname: Wagner
authors.forename: Christian
authors.initials: C
authors.lastname: Joukhadar
mesh_terms: D000293:Adolescent; D000328:Adult; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D016207:Cytokines / Q000097:blood*; D019446:Endotoxemia / Q000276:immunology*; D005578:Fosfomycin / Q000494:pharmacology*; D006801:Humans; D053583:Interleukin-1beta / Q000097:blood; D015850:Interleukin-6 / Q000097:blood; D008070:Lipopolysaccharides / Q000633:toxicity; D008297:Male; D011446:Prospective Studies; D014409:Tumor Necrosis Factor-alpha / Q000097:blood
chemical_list: D000900:Anti-Bacterial Agents; D016207:Cytokines; D053583:Interleukin-1beta; D015850:Interleukin-6; D008070:Lipopolysaccharides; D014409:Tumor Necrosis Factor-alpha; D005578:Fosfomycin